Highlights
- 1Gastroenterology · 2021
- 2Gastroenterology · 2020
- 3Cell host & microbe · 2021
Publications
Funding
Active
15 grants- Co-IR01AI184474-01A1Molecular Programs Governing Enterococcal TranslocationNational Institute of Allergy and Infectious Diseases · 2025–2030
- MPIT32DK116970-07Multidisciplinary Research Training in Gastroenterology and HepatologyNational Institute of Diabetes and Digestive and Kidney Diseases · 2019–2030Training· 3 renewals
- PIBP 265072-01TL1A-Induced GM-CSF Shapes Innate Immune Memory Linking Colitis with Systemic Inflammatory ToneSanofi S.A. · 2026–2029BioPharma Alliance
- MPIR01AT013241-02Activity Probes to Guide Precision Microbiome TherapyNational Center for Complementary and Integrative Health · 2024–2029
- PIR01DK140463-02Agr2 regulates host-microbe responses in Crohn's diseaseNational Institute of Diabetes and Digestive and Kidney Diseases · 2025–2029
- PIR01DK120985-06TL1A Regulation of Group 3 Innate Lymphoid Cells in ColitisNational Institute of Diabetes and Digestive and Kidney Diseases · 2020–2029· 2 renewals
- Co-IR01DK137299-01A1Optimization of small molecule immunomodulators as combination therapy for IBDNational Institute of Diabetes and Digestive and Kidney Diseases · 2024–2029
- KP1447818Colitis drive tumor promoting neutrophils and shapes bone marrow progenitors.Crohn's and Colitis Foundation of America · 2025–2028
- PIBP 231752-01Molecular and clinical characterization of IBD patients naive or refractory to standard of care over timeBoehringer Ingelheim Pharmaceuticals, Inc. (Germany) · 2023–2028BioPharma Alliance
- Co-IR01CA273106-01Tumor selective inhibition of the WNT pathwayNational Cancer Institute · 2022–2027
- PICCFA 1616748Assessing immunomodulation of VE202 live biotherapeutic product in UCCrohn's and Colitis Foundation of America · 2026–2027
- KPKL2TR002385-06Clinical and Translational Science Center - KL2National Center for Advancing Translational Sciences · 2022–2027
- Sub-PI2311-06388Standardized Microbiota Transplant Therapy in Crohn's Disease, Pilot TrialThe Leona M. and Harry B. Helmsley Charitable Trust · 2024–2027 · via University of Minnesota
- KP2311-06390Targeting the mycobiome in patients with Crohn’s DiseaseThe Leona M. and Harry B. Helmsley Charitable Trust · 2023–2027
- PI1165475Fiber-induced Metabolites Promote UC HealingCrohn's and Colitis Foundation of America · 2024–2026
Completed grants (16)
- KPCCFA 953817Role for TL1A in innate intestinal inflammation and colitis associated cancerCrohn's and Colitis Foundation of America · 2022–2025
- Co-IR01AI151038-01Screening for Resistant Enteric Bacteria to Personalize Infection Prevention Strategies in Neutropenic PatientsNational Institute of Allergy and Infectious Diseases · 2020–2025
- PIR01DK128257-03A randomized, placebo-controlled clinical trial examining the efficacy of Fecal Microbiota Transplantation (FMT) and subsequent dietary fiber in patients with moderate ulcerative colitis (MINDFUL)National Institute of Diabetes and Digestive and Kidney Diseases · 2021–2025
- KPCCFA #877970Microbes invading mesenteric adipose tissue drive pathogenic anti-microbial IgGCrohn's and Colitis Foundation of America · 2023–2024
- PIP 234168-01Emerging Therapeutic Paradigms in Inflammatory Bowel DiseasePfizer Inc. · 2023–2024
- Sub-PIUT 10054865-03Anti-phage antibodies in stratifying Crohn's disease diagnosis and treatment responseLeona M. and Harry B. Helmsley Charitable Trust, The · 2019–2023 · via University of Utah
- PIR01DK114252-05Host-Microbiota Interactions in Crohn's Disease-Associated SpondyloarthritisNational Institute of Diabetes and Digestive and Kidney Diseases · 2018–2023
- KPKRF 2019-1435The Impact of Time Restricted Feeding in Crohn's DiseaseKenneth Rainin Foundation · 2019–2022
- KPCCFA 637661Cellular and Microbial regulation of Crohn's disease AIEC Th17 immunityCrohn's and Colitis Foundation of America · 2019–2022Fellowship
- PIKRF 2019-1419Cell-free DNA as a non-invasive test of bacterial translocation, ileal inflammation, and extra-internal Crohn's diseaseKenneth Rainin Foundation · 2019–2022
- PICCFA 213661-01The efficacy of Fecal Microbiota Transplantation (FMT) and subsequent dietary fiber in patients with moderate Ulcerative Colitis (MINDFUL)Crohn's and Colitis Foundation of America · 2019–2021
- PIBP 170619-03SHINE Collaboration Framework Agreement: Strategy and Platforms to Define Transferable Therapeutic Microbiota for Inflammatory DiseaseBoehringer Ingelheim · 2017–2020Contract
- PIR03DK111852-02Investigating Microbial Regulation of Intestinal Mononuclear Phagocyte Production of TL1A in ILC3-Dependent Barrier ImmunityNational Institute of Diabetes and Digestive and Kidney Diseases · 2017–2019
- PINYCF 181675-01Defining Immunologically Relevant Microbiota in CD-associated SpondyloarthritisNew York Crohn's Foundation · 2017–2019
- PIR21CA201829-02Mechanisms of Orthotopic Human Colorectal Cancer Growth in Immunocompetent MiceNational Cancer Institute · 2016–2018
- PIK08DK099381-05The Function and Microbial Regulation of Innate Lymphoid Cells in IBDNational Institute of Diabetes and Digestive and Kidney Diseases · 2013–2018Career
Honors & distinctions
- Member · American Society for Clinical Investigation · 2022
Clinical research
Active
3 studies- PINCT06631586Standardized Microbiota Transplant Therapy in Crohn's DiseasePHASE2 · University of Minnesota · OPEN TO ACCRUAL (as of 2025)Crohn Disease
- PINCT06430801A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderately to Severely Active Crohn's DiseasePHASE3 · Merck & Co., Inc. · OPEN TO ACCRUAL (as of 2025)Crohn's Disease
- PINCT06274554A Prospective, Randomized, Placebo-controlled Trial of Fluconazole in Combination With IL-23 Therapy Versus IL-23 Therapy Alone for the Treatment of Crohn's DiseasePHASE3 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)Crohn's Disease; Inflammatory Bowel Diseases
Completed & closed trials (7)
- PINCT06588855A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative ColitisPHASE3 · F. Hoffmann-La Roche AG · CLOSED TO ACCRUAL (as of 2026)Moderately to Severely Active Ulcerative Colitis
- PINCT05013905A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's DiseasePHASE2 · Prometheus Biosciences, Inc · IRB STUDY CLOSURE (as of 2024)Crohn Disease
- PINCT04996797A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative ColitisPHASE2 · Prometheus Biosciences, Inc · IRB STUDY CLOSURE (as of 2024)Ulcerative Colitis
- PINCT03998488A Randomized, Placebo-controlled Clinical Trial Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Subsequent Dietary Fiber in Patients With Moderate Ulcerative ColitisPHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)Ulcerative Colitis; Inflammatory Bowel Diseases
- PIPhaRmacokinEtic and pharmacoDynamics of therapies, non-Inflammatory surgical Complications and predicTive biomarkers in pOst-opeRative crohn?s disease study (PREDICT-OR)Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2022)
- PINCT03893565A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative ColitisPHASE2 · GlaxoSmithKline · IRB STUDY CLOSURE (as of 2022)Colitis, Ulcerative
- PINCT03558152A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative ColitisPHASE2 · Genentech, Inc. · IRB STUDY CLOSURE (as of 2021)Ulcerative Colitis
Available technologies
- Microbiome Theranostic for Sulfasalazine Treatment in Patients with IBD-Associated Spondyloarthritis11070Application filedPoC DataPMID 38378002
- Transferable Microbiota for the Treatment of Ulcerative Colitis9296Application filedPoC DataPMID 34606847
News mentions
- Key Gut Protein Balances Immune Protection and ToleranceJuly 7, 2026
A protein produced by gut immune cells orchestrates both immune protection against pathogens and immune tolerance of gut bacteria, according to a study led by Weill Cornell Medicine investigators.
- Discovery Illuminates How Inflammatory Bowel Disease Promotes Colorectal CancerJanuary 22, 2026
A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone marrow—may help explain why people with inflammatory bowel disease (IBD) have a higher risk of colorectal cancer, according to a study by Weill Cornell Medicine investigators.
- Possible Biomarker Identified for Crohn’s Disease with Arthritis TypeMarch 5, 2025
People with Crohn’s disease and related joint inflammation linked to immune system dysfunction have distinct gut bacteria or microbiota, with the bacterium Mediterraneibacter gnavus being a potential biomarker, according to new study by Weill Cornell Medicine researchers.
- Dr. Randy Longman Receives NIH Director’s Transformative Research AwardOctober 8, 2024
Dr. Randy Longman, director of the Jill Roberts Center for Inflammatory Bowel Disease and an associate professor of medicine at Weill Cornell Medicine, and colleagues have received the NIH Director’s Transformative Research Award to develop the tools needed to understand how the gut microbiome drives metabolic pathways.
- New Insight into How an Old IBD Drug WorksFebruary 20, 2024
Researchers at the Jill Roberts Center for IBD and the Jill Roberts Institute for Research in IBD at Weill Cornell Medicine and NewYork-Presbyterian have determined that sulfasalazine works by modulating the activity of a group of gut bacteria that are more abundant in patients who respond to the drug.
Show 5 more mentions
- Grant Awarded to Investigate Antifungal Therapies in Crohn’s PatientsJune 15, 2023
Dr. Iliyan D. Iliev, an associate professor of immunology in medicine in the Division of Gastroenterology and Hepatology, co-director of the Microbiome Core and a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease (IBD) at Weill Cornell Medicine, is the lead investigator on a grant to Weill Cornell Medicine from The Leona M. and Harry B. Helmsley Charitable Trust to target pathogenic fungi in patients with Crohn’s disease.
- To Trigger Crohn’s Disease, Pathogenic Bacteria Co-opt a Genetic SusceptibilityDecember 1, 2022
Changes in a single gene open the door for harmful gut bacteria to set off the inflammation that drives Crohn’s disease.
- Two Weill Cornell Medicine Faculty Members Inducted into ASCIFebruary 18, 2022
Two Weill Cornell Medicine physician-scientists, Dr. Randy Longman and Dr. Robert Schwartz, have been elected as members of the American Society for Clinical Investigation.
- Researchers Identify Bacteria That Underlie Success of Fecal Microbiota TransplantsOctober 11, 2021
The effectiveness of fecal microbiota transplantation (FMT) in treating ulcerative colitis depends on a small set of beneficial bacterial strains, suggests a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
- Study Identifies ‘Achilles heel’ of Bacteria Linked to Crohn’s DiseaseFebruary 5, 2021
The discovery of an “Achilles heel” in a type of gut bacteria that causes intestinal inflammation in patients with Crohn’s disease may lead to more targeted therapies for the difficult to treat disease.
Mentoring
- SLSvetlana LimaPostdoc mentee · 2021–2023
- MNManabu NagayamaPostdoc mentee · 2022–2025
- MMMaeva MetzImmunology & Microbial Pathogenesis (PhD) · Class of 2022
- ECEmre CardakliMD-PhD WGS Immunology & Microbial Pathogenesis (MD-PhD)
- DLDaniel LaiMD mentee · Class of 2023
- RARafael AlmanzarMD mentee · Class of 2024
- CXChristopher XanthosMD mentee · Class of 2019
- ARAmanda RupertMD mentee · Class of 2018
External relationships
Advisory/Scientific Board Member
CJ CheilJedang Corp.
Other
Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · Merck & Co., Inc. · Sanofi S.A. · Shattuck Labs · Spyre Therapeutics INC · Vedanta Biosciences, Inc. · Xencor INC.